
GlaxoSmithKline (GSK) and Pfizer are holding out for an improved bid of at least £60 billion (US$82 billion) for their consumer healthcare joint venture, bolstered by shareholder opposition to Unilever’s £50 billion (US$68.4 billion) offer, reported The Financial Times.
GSK dismissed Unilever’s bid on Saturday, January 15, as “fundamentally undervalued”, as it revealed improved forecasts for the business. A 25% premium to the estimated value of the business — which would push a bid above £60 billion — would warrant serious consideration from the board, according to one person close to Pfizer. Another person familiar with the matter said it would be “hard to turn down.”
GSK had been planning to spin off the unit, in which it owns a 68%t stake, but has been under pressure to consider a sale, including from US hedge fund Elliott Management.
Marco Taricco, co-chief investment officer at Bluebell Capital Partners, another activist investor pushing for GSK to consider a sale, said, “Based on the limited information we have so far, £50bn sounds like a floor, but it should be improved, either by Unilever or by someone else.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Australia’s Major Supermarkets Face Scrutiny Over Profit Margins Amid Rising Prices
Mar 21, 2025 by
CPI
Fired FTC Commissioners Warn of Potential White House Influence Over Mergers
Mar 20, 2025 by
CPI
Dr. Matthew Backus Joins Compass Lexecon as an Affiliate
Mar 20, 2025 by
CPI
UK to Boost Broadband Competition While Capping Openreach Charges, Says Ofcom
Mar 20, 2025 by
CPI
Singapore Competition Watchdog Yet to Receive Formal Notification on Grab-GoTo Merger
Mar 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li